{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:58:52Z","timestamp":1768557532661,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Medical Research Center, Hamad Medical Corporation, Qatar","award":["MRC-01-21-987"],"award-info":[{"award-number":["MRC-01-21-987"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>The pharmacologic management of patent ductus arteriosus (PDA) presents a challenge to clinicians due to the interindividual variability in drug response to available medications. There is evidence that CYP2C9 is associated with the response to PDA treatment; however, no data from the Middle East is available. This study aimed to investigate the association between CYP2C8 and CYP2C9 genetic polymorphisms and response to ibuprofen or indomethacin in neonates with PDA. We conducted a retrospective cohort study of neonates with a gestational age &lt; 32 weeks and birthweight &lt; 1500 g with PDA between 2019 and 2023. Eligible neonates were those diagnosed with PDA and treated with at least one course of ibuprofen or indomethacin. Genotyping was performed to identify four single-nucleotide polymorphisms (SNPs), namely CYP2C8*3 rs10509681, CYP2C9*2 rs1799853, CYP2C9 rs2153628, and CYP2C9*3 rs1057910. Allele frequencies were compared between responders and non-responders, and non-genetic predictors were assessed using logistic regression. A total of 146 infants were identified. Of these, 86 were enrolled. Genetic analysis showed that the heterozygote genotype (TC) for the CYP2C8 gene was the most common (45%), while wild-type alleles were predominant for CYP2C9 variants. No significant differences in allele frequencies were found between responders and non-responders to the treatment (p &gt; 0.05). In a secondary analysis, the need for multiple surfactant doses independently predicted poor response (aOR 0.244, 95% CI 0.086\u20130.693, p = 0.008), while extremely low birth weight showed a borderline association (aOR 0.281, 95% CI 0.062\u20131.268, p = 0.099). Carriers of CYP2C8*3 rs10509681, CYP2C9*2 rs1799853, CYP2C9 rs2153628, and CYP2C9*3 rs1057910 were not associated with variations in response to NSAIDs.<\/jats:p>","DOI":"10.3390\/jcdd13010049","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:35:38Z","timestamp":1768487738000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of CYP2C8 and CYP2C9 Polymorphisms in Neonates with Patent Ductus Arteriosus Treated with Ibuprofen or Indomethacin: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Shaikha Jabor","family":"Alnaimi","sequence":"first","affiliation":[{"name":"Pharmacy Department, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimaa","family":"Aboelbaha","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Safra","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-9680","authenticated-orcid":false,"given":"Mai Abdulla","family":"Al Qubaisi","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Abounahia","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7257-0588","authenticated-orcid":false,"given":"Ahmed","family":"Al Farsi","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"},{"name":"London Health Sciences Center, Western University, London, ON N6A 3K7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liji","family":"Cherian","sequence":"additional","affiliation":[{"name":"Baby Clinic, Outpatient Department, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizy","family":"Philip","sequence":"additional","affiliation":[{"name":"Baby Clinic, Outpatient Department, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moza","family":"Alhail","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulab","family":"Sher","sequence":"additional","affiliation":[{"name":"Research Department and Translational and Precision Medicine Research, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-1135","authenticated-orcid":false,"given":"Nader","family":"Al-Dewik","sequence":"additional","affiliation":[{"name":"Research Department and Translational and Precision Medicine Research, Women\u2019s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1399-0004.1999.560401.x","article-title":"Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?","volume":"56","author":"Nebert","year":"1999","journal-title":"Clin. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/wps.20371","article-title":"Right patient, right treatment, right time: Biosignatures and precision medicine in depression","volume":"15","author":"Trivedi","year":"2016","journal-title":"World Psychiatry"},{"key":"ref_3","first-page":"105","article-title":"Clinical Application of Pharmacogenetics: Where are We Now?","volume":"24","year":"2013","journal-title":"Ejifcc"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/pme.13.70","article-title":"Pharmacogenetics in clinical pediatrics: Challenges and strategies","volume":"10","author":"McGregor","year":"2013","journal-title":"Pers. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bcp.13526","article-title":"Developmental pharmacogenetics of CYP2C19 in neonates and young infants: Omeprazole as a probe drug","volume":"84","author":"Zhao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"F505","DOI":"10.1136\/archdischild-2013-303816","article-title":"Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3","volume":"98","author":"Sellmer","year":"2013","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1542\/peds.2009-3506","article-title":"Patent ductus arteriosus of the preterm infant","volume":"125","author":"Hamrick","year":"2010","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e025784","DOI":"10.1161\/JAHA.122.025784","article-title":"Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider","volume":"11","author":"Backes","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lee, L.C., Tillett, A., Tulloh, R., Yates, R., and Kelsall, W. (2006). Outcome following patent ductus arteriosus ligation in premature infants: A retrospective cohort analysis. BMC Pediatr., 6.","DOI":"10.1186\/1471-2431-6-15"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10689","DOI":"10.1038\/s41598-021-89868-z","article-title":"Patent ductus arteriosus treatment trends and associated morbidities in neonates","volume":"11","author":"Park","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1038\/jp.2008.52","article-title":"Treatment of patent ductus arteriosus: Indomethacin or ibuprofen?","volume":"28","author":"Sekar","year":"2008","journal-title":"J. Perinatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00431-004-1596-5","article-title":"A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus","volume":"164","author":"Thomas","year":"2005","journal-title":"Eur. J. Pediatr."},{"key":"ref_13","first-page":"Cd003481","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm and\/or low birth weight infants","volume":"30","author":"Ohlsson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","first-page":"Cd003481","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants","volume":"2","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","first-page":"Cd013133","article-title":"Indomethacin for symptomatic patent ductus arteriosus in preterm infants","volume":"1","author":"Evans","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamapediatrics.2016.5143","article-title":"Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants","volume":"171","author":"Weisz","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/pr.2017.145","article-title":"Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus","volume":"82","author":"Smith","year":"2017","journal-title":"Pediatr. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10601330500214559","article-title":"Cytochrome P450 Gene Polymorphisms and Variability in Response to NSAIDs","volume":"22","author":"Blanco","year":"2005","journal-title":"Clin. Res. Regul. Aff."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/aiht-2016-67-2754","article-title":"How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity","volume":"67","author":"Krasniqi","year":"2016","journal-title":"Arh. Hig. Rada Toksikol."},{"key":"ref_20","unstructured":"Benitz, W.E., and Smith, P.B. (2019). Chapter 12\u2014Neonatal Pharmacogenetics. Infectious Disease and Pharmacology, Elsevier."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s43657-021-00028-9","article-title":"CYP2C9*3 Increases the Ibuprofen Response of Hemodynamically Significant Patent Ductus Arteriosus in the Infants with Gestational Age of More Than 30 Weeks","volume":"2","author":"Chen","year":"2022","journal-title":"Phenomics"},{"key":"ref_22","unstructured":"HCY (2023, August 13). 150 mm Medical Disposable Sampling Tube for Saliva Collecting. Available online: https:\/\/icleanswabs.com\/."},{"key":"ref_23","unstructured":"PROMEGA (2023, August 13). Maxwell\u00ae 16 DNA Purification Kits Technical Manual. Available online: https:\/\/worldwide.promega.com\/resources\/protocols\/technical-manuals\/0\/maxwell-16-dna-purification-kits-protocol\/."},{"key":"ref_24","unstructured":"Thermo Fisher Scientific (2023, August 13). NanoDrop\u2122 2000\/2000c Spectrophotometers. Available online: https:\/\/www.thermofisher.com\/order\/catalog\/product\/ND-2000."},{"key":"ref_25","unstructured":"Thermo Fisher Scientific (2023, August 13). TaqMan\u2122 Drug Metabolism Genotyping Assay. Available online: https:\/\/www.thermofisher.com\/order\/catalog\/product\/4362691?SID=srch-srp-4362691."},{"key":"ref_26","unstructured":"Thermo Fisher Scientific (2023, August 13). TaqMan\u2122 SNP Genotyping Assay, Human. Available online: https:\/\/www.thermofisher.com\/order\/catalog\/product\/4331349?SID=srch-srp-4331349."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1017\/S1047951119001033","article-title":"Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants","volume":"29","author":"Sallmon","year":"2019","journal-title":"Cardiol. Young"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1542\/peds.2008-0313","article-title":"Determination of genetic predisposition to patent ductus arteriosus in preterm infants","volume":"123","author":"Dagle","year":"2009","journal-title":"Pediatrics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1017\/S1047951115001869","article-title":"Surgical ligation of patent ductus arteriosus in premature infants: Trends and practice variation","volume":"26","author":"Weinberg","year":"2016","journal-title":"Cardiol. Young"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41372-018-0285-6","article-title":"Genetic variants associated with patent ductus arteriosus in extremely preterm infants","volume":"39","author":"Dagle","year":"2019","journal-title":"J. Perinatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.semperi.2018.05.008","article-title":"Changing patterns of patent ductus arteriosus surgical ligation in the United States","volume":"42","author":"Reese","year":"2018","journal-title":"Semin. Perinatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ibrahim, T., Abdul Haium, A.A., Tapawan, S.J., Dela Puerta, R., Allen, J.C., Chandran, S., Chua, M.C., and Rajadurai, V.S. (2020). Selective Treatment of PDA in High-Risk VLBW Infants With Birth Weight \u2264800 g or <27 Weeks and Short-Term Outcome: A Cohort Study. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.607772"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs-2019-0079","article-title":"CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus","volume":"20","author":"Rooney","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41390-023-02578-2","article-title":"Patent ductus arteriosus, bronchopulmonary dysplasia and pulmonary hypertension\u2014A complex conundrum with many phenotypes?","volume":"94","author":"Mullaly","year":"2023","journal-title":"Pediatr. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"151718","DOI":"10.1016\/j.semperi.2023.151718","article-title":"Patent ductus arteriosus (PDA) and pulmonary morbidity: Can early targeted pharmacologic PDA treatment decrease the risk of bronchopulmonary dysplasia?","volume":"47","author":"Clyman","year":"2023","journal-title":"Semin. Perinatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jpeds.2020.09.047","article-title":"Prolonged Tracheal Intubation and the Association Between Patent Ductus Arteriosus and Bronchopulmonary Dysplasia: A Secondary Analysis of the PDA-TOLERATE trial","volume":"229","author":"Clyman","year":"2021","journal-title":"J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41372-020-0718-x","article-title":"The effect of prolonged tracheal intubation on the association between patent ductus arteriosus and bronchopulmonary dysplasia (grades 2 and 3)","volume":"40","author":"Clyman","year":"2020","journal-title":"J. Perinatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/00498254.2021.1982070","article-title":"Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosus","volume":"51","author":"Sridharan","year":"2021","journal-title":"Xenobiotica"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/1\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:14:59Z","timestamp":1768490099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/1\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcdd13010049"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13010049","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}